REG - Diaceutics PLC - Diaceutics Launches Enhanced Rare-Disease Offering

DiaceuticsAnnouncement

27/08/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240827:nRSa5974Ba&default-theme=true

RNS Number : 5974B  Diaceutics PLC  27 August 2024

Diaceutics Launches Enhanced Rare-Disease Offering

 

Significant expansion of lab network will deliver more rare-disease data

 

New contract signed to support the commercialisation of a rare-disease therapy

 

Belfast and London, 27 August 2024 - Diaceutics PLC (AIM: DXRX), a leading
technology and solutions provider to the pharma and biotech industry, is
pleased to announce a significant enhancement to its offering which has
facilitated a new rare-disease contract win. Access to this new data will
revolutionise the early identification of patients, a crucial growth area for
pharma companies developing therapies for rare-diseases. Leveraging
cutting-edge data utilisation, it will improve earlier patient diagnosis and
ultimately, clinical outcomes.

 

Driving this enhancement are 3 key developments within the Diaceutics business
as follows:

 

 1.        Onboarding of New Data Partners: A number of new rare-disease genomic lab data
           partners have joined the DXRX network. These partners specialise in genetic
           testing, including the largest recognised testing lab in the United States for
           genetically acquired rare diseases.

 2.        Advanced Lab Labelling Natural Language Processing (NLP): Diaceutics has
           updated its advanced lab labelling NLP process to standardise and add value to
           the new data. This process enables complex labelling such as pathogenic vs
           Variants of Unknown Significance (VUS) variant calling which until now has
           proven challenging for the industry to identify.

 3.        Access to Additional Industry Experts: The company now has a team of industry
           experts with deep rare-disease experience to support biopharma business
           opportunities and ensure clients derive maximum value from Diaceutics'
           deep-data offering.

 

Jordan Clark, Chief Data Officer of Diaceutics commented: "These enhancements
to our rare-disease data offering represent significant progress in our
mission to support the earlier identification and treatment of patients with
rare diseases. By integrating new data, advanced labelling and a specialised
team, we are well-positioned to address the critical needs of this underserved
market and help patients in need."

 

Susanne Munksted, Chief Precision Medicine Officer of Diaceutics, commented:
"Diaceutics is uniquely positioned to support pharma clients in the
challenging and complex area of rare diseases. Our business model is unique in
that we combine best in class data with disease experts who have a passion for
precision medicine and improving patient outcomes."

 

Despite medical and scientific advances, diagnosing rare diseases remains a
significant challenge for biopharma companies. Many patients face years of
multiple referrals, inconclusive test results and limited treatment benefits.
Early diagnosis and quick interventions are crucial for patient survival and
quality of life. A precision medicine approach can end these diagnostic
odysseys and open opportunities for better clinical outcomes for patients in
need.

 

The strategic enhancements announced today will enable Diaceutics to identify
more patients earlier and in doing so, help pharma customers to better
commercialise gene therapies for rare diseases. Leveraging these business
enhancements, Diaceutics has already secured a new contract to provide a
multi-product solution to support the commercialisation of a therapy in a rare
autosomal-recessive disease. This initial contract win demonstrates
Diaceutics' ability to meet the complex needs of this market.

 

This announcement contains inside information for the purposes of Article 7 of
Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the
European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance
with the Company's obligations under Article 17 of MAR. The person responsible
for making this announcement on behalf of the Company is Nick Roberts, Chief
Financial Officer.

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome. We provide the world's leading pharma and biotech companies
with an end-to-end commercialisation solution for precision medicines through
data analytics, scientific and advisory services enabled by our platform DXRX
- The Diagnostics Network®.

 

Enquiries:

 Diaceutics PLC
 Ryan Keeling, Chief Executive Officer                  Tel: +44 (0)28 9040 6500

 Nick Roberts, Chief Financial Officer                  investorrelations@diaceutics.com

 Stifel Nicolaus Europe Limited (Nomad & Broker)        Tel: +44 (0)20 7710 7600
 Ben Maddison, Nick Harland, Kate Hanshaw

 Alma Strategic Communications                          Tel: +44(0)20 3405 0205
 Caroline Forde, Kinvara Verdon, Kieran Breheny         diaceutics@almastrategic.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFIFFTTVIVFIS